From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy

American Journal of Transplantation

Volumn 4, Issue 3, 2004, Pages 299-310

  Cattaneo, Dario ^a   Perico, Norberto ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Genomics; Immunosuppressive agents; Pharmacogenetics; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TEMSIROLIMUS;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG TRANSPORT; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENETIC ANALYSIS; GENETIC CODE; GENETIC POLYMORPHISM; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEUROTOXICITY; ORGAN TRANSPLANTATION; PHARMACOGENOMICS; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT;

AZATHIOPRINE; CALCINEURIN; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PHARMACOGENETICS;

EID: 1442314112     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00312.x     Document Type: Short Survey

References (102)

1. Benet LZ. Relevance of pharmacokinetics in narrow therapeutic index drugs. Transplant Proc 1999; 31: 1642-1644.
2. Lindholm A, Sawe J. Pharmacokinetics and therapeutic drug monitoring of immunosuppressants. Ther Drug Monit 1995; 17: 570-573.
3. Danesi R, Mosca M, Boggi U, Del Tacca M. Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. Mol Med Today 2000; 6: 475-482.
4. Johnston A, Holt DW. Immunosuppressant drugs - the role of therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52: 61S-73S.
5. Grant D, Kneteman N, Tchervenkov J et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 1999; 67: 1133-1137.
6. van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the acute rejection after kidney transplantation. Transplantation 1999; 68: 261-266.
7. Kahan BD, Napoli KL, Kelly PA et al. Therapeutic drug monitoring of sirolimus: correlation with efficacy and toxicity. Clin Transplant 2000; 14: 97-109.
8. Mahalati K, Belitski P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentrationtime curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55-62.
9. Backman L, Levy MF, Klintmalm G. Whole-blood and plasma levels of FK-506 after liver transplantation: results from the US multicenter trial. Transplant Proc 1995; 27: 1124.
10. Yagil Y, Yagil C. Insights into pharmacogenomics and its impact upon immunosuppressive therapy. Transplant Immunology 2002; 9: 203-209.
11. Kalow W. The Pennsylvenia State University College of Medicine Bernard B. Brodie Lecture: pharmacogenetics: past and future. Life Sci 1990; 47: 1385-1397.
12. Lander ES, Lintom LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
13. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
14. Bates D, Gawande A. Error in medicine: what have we learned? Ann Intern Med 2000; 132: 763-767.
15. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions - a systematic review. JAMA 2001; 286: 2270-2279.
16. Wolf C, Smith G. Pharmacogenetics. Br Med Bull 1999: 55:366-386.
17. Meyer UA. Pharmacogenetics and adverse drug reaction. Lancet 2000; 356: 1667-1671.
18. Lindpainter K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat Rev Drug Disc 2002; 1: 463-469.
19. Weber L. High-diversity combinatorial libraries. Curr Opin Chem Biol 2000; 4: 295-302.
20. Bonnie A, Fijal MS, Hall JM, Witte JS. Clinical trials in the genomic era. Effects of protective genotypes on sample size and duration of trial 2000. Control Clin Trials 2000; 21: 7-20.
21. McCarthy JJ, Hilfiker R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nature Biotechnology 2000; 18: 505-508.
22. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-11829.
23. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453-470.
24. Jain KK. Applications of biochip and microarray systems in pharmacogenomics. Pharmacogenomics 2000; 1: 289-307.
25. Rininger JA, DiPippo VA, Gould-Rothberg BE. Differential gene expression technologies for identifying surrogate markers of drug efficacy and toxicity. Drug Discovery Today 2000; 5: 560-568.
26. Disney AP. Complications of immunosuppressive therapy in transplantation. 1: neoplasia and infection. Med J Aust 1992; 157: 262-264.
27. Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for the therapeutic drug monitoring. Clin Chem 1998; 44: 381-387.
28. Kalow W, Gunn DR. Some statistical data on atypical cholinesterase of human serum. Ann Hum Genet 1959; 23:239-250.
29. Anonimous. The relation between dose of succinylcoline and duration of apnea in man. J Pharmacol Exp Ther 1957; 120: 203-214.
30. Price Evans DA, Manley KA, McKusick VA. Genetic control of isonazid metabolism in the man. BMJ 1960; 2: 485-491.
31. Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens 2002; 11: 657-663.
32. Usui T, Saitoh Y, Komada F. Induction of CYP3A5 in hepG2 cells by several drugs. - Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull 2003; 26: 510-517.
33. Kim RB. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 2002; 12: 425-427.
34. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for use of azathioprine in transplant recipients. Transplantation 1992; 53: 1051-1056.
35. Elion G. The purine path to chemotherapy. Science 1989; 244: 41-47.
36. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-652.
37. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine-S-methyltransferase paradigm. Pharm Res 1999; 16: 342-349.
38. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89-98.
39. Szumlanski C, Otterness D, Her C et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15: 17-30.
40. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Int Med 1997; 126: 608-614.
41. Sebbarg L, Boucher P, Davelu P et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 2000; 69: 1524-1527.
42. Schutz E, Gummert J, Armstrong VW, Mohr FW, Oellerich M. Azathioprine pharmacogenetics. the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 1996; 34: 199-205.
43. Dervieux T, Medard Y, Baudouin V et al. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediaric renal transplant recipients treated with azathioprine. Br J Clin Pharmacol 1999; 48: 793-800.
44. Thervet E, Anglicheau D, Toledano N, Kreis H, Legendre CH, Beaune P. Clinical consequences of the polymorphism of azathioprine metabolism. Transplant Proc 2000; 32: 2780-2781.
45. Ohlman S, Albertioni F, Peterson C. Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. Clin Transplant 1994; 8: 217-223.
46. Bergan S, Rugstad HE, Bentdal O et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation 1998; 66: 334-339.
47. Yatscoff RW, Aspeslet LJ, Gallant HL. Pharmacodynamic monitoring of immunosuppressive durgs. Clin Chem 1998; 44: 428-432.
48. Falta MT, Atkinson MA, Allegretta M, Vacek PM, Albertini RJ. Azathioprine associated T-cell mutations in insulindependent diabetes mellitus. Scand J Immunol 2000; 51: 626-633.
49. Albertini RJ, Castle KL, Borcherding WR. T-cell cloning to detect the mutant 6-thioguanine-resistant lymphocytes present in human peripheral blood. Proc Natl Acad Sci USA 1982; 79:6617-6621.
50. Tates AD, van Dam FJ, van Mossel H et al. Use of the clonal assay for the measurement of frequencies of HPRT mutants in T-lymphocytes from five control populations. Mutation Res 1991; 253: 199-213.
51. Robinson D, Goodal K, Albertini RJ et al. An analysis of in vivo hprt mutant frequency in circulating T-lymphocytes in the normal human population: a comparison of four databases. Mutation Res 1994; 313: 227-247.
52. Ansari AA, Mayne A, Sundstrom JB et al. Frequency of hypoxanthine guanine phosphoribosyltransferase (HPRT) T cells in the peripheral blood of cardiac transplant recipients: a noninvasive technique for the diagnosis of allograft rejection. Circulation 1995; 92: 862-874.
53. Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-1145.
54. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278-298.
55. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268: 27286-27290.
56. Zimmermann AG, Wright KL, Ting JP, Mitchell BS. Regulation of inosine-5′-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5′ palindromic octamer sequence. J Biol Chem 1997; 272: 22913-22923.
57. Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999; 65: 640-648.
58. Shipkova M, Armstrong VW, Wieland E et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999; 126: 1075-1082.
59. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003; 3: 136-158.
60. Mackenzie PI. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 2000; 22: 10-13.
61. Cattaneo D, Gaspari F, Ferrari S et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001; 15: 402-409.
62. Mackenzie PI, Miners JO, McKinnon RA. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 2000; 38: 889-892.
63. Ando Y, Saka H, Sawa T et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
64. Huang YH, Galijatovic A, Nguyen N et al. Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGTA8*3. Pharmacogenetics 2002; 12: 287-297.
65. Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62: 608-617.
66. Sollinger H. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
67. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
68. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
69. Futer O, Sintchak MD, Caron PR et al. A mutational analysis of the active site of human type II inosine 5′-monophosphate dehydrogenase. Biochim Biophys Acta 2002; 1594: 27-39.
70. Digits JA, Hedstrom L. Species-specific inhibition of inosine 5′-monophosphate dehydrogenase by mycophenolic acid. Biochemistry 1999; 38: 15388-15397.
71. Bowne SJ, Sullivan LS, Blanton SH et al. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum Mol Genet 2002; 11: 559-568.
72. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
73. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-1229.
74. Sata F, Sapone A, Elizondo G et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000; 67: 48-56.
75. Rivory LP, Qin H, Clarke SJ et al. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporine clearance. Eur J Clin Pharmacol 2000; 56: 395-398.
76. von Ansen N, Richter M, Grupp C, Ringe B, Oellerich M, Amstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048-1052.
77. Min DI, Ellingrod VL. Association of the CYP3A4*1 B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2003; 25: 305-309.
78. Westlind A, Lofberg L, Tindberg N, Andresson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999; 259: 201-205.
79. Hsieh KP, Lin YY, Cheng CL et al. Novel mutations of CYP3A4 in chinese. Drug Metab Dispos 2001; 29: 268-273.
80. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 2001; 27: 383-391.
81. van Schaik RHN, van der Hieden IP, van der Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch caucasians. Clin Chem 2002; 48: 1668-1671.
82. Zheng H, Webber S, Zeevi A et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3: 477-483.
83. Macphee IA, Federicks S, Tai T et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and p-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-1489.
84. Tanabe M, Ieiri I, Nagata N et al. Expression of p-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR) -1 gene. J Pharmacol Exp Ther 2001; 297: 1137-1143.
85. Hoffmeyer S, Burk O, Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
86. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among european americans and african americans. Clin Pharmacol Ther 2001; 70: 189-199.
87. Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2002; 24: 400-404.
88. Yamauchi A, Ieiri I, Kataoka Y et al. Neurotoxicity indiced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002; 74: 571-578.
89. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
90. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJD. Genetic polymorphisms in MDR1 and CYP3A4 genes in asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89-95.
91. Anglicheau D, Verstuyft C, Laurent-Puig P et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889-1896.
92. Zhu D, Cardenas ME, Heitman J. Calcineurin mutants render T lymphocytes resistant to cyclosporin A. Mol Pharmacol 1996; 50: 506-511.
93. Fruman DA, Pai SY, Burakoff SJ, Bierer BE. Characterization of a mutant calcineurin A alpha gene expressed by EL4 lymphoma cells. Mol Cell Biol 1995; 15: 3787-3863.
94. Brogan IJ, Pravica V, Hutchinson IV. Genetic conservation of the immunophilin-binding domains of human calcineurin A1 and A2. Transplant Immunol 2000; 8: 139-141.
95. Conti F, Breton S, Batteux F et al. Defective interleukin-1 receptor antagonist production is associated with resistance of acute liver graft rejection to steroid therapy. Am J Pathol 2000; 157: 1685-1692.
96. Yudt MR, Cidlowski JA. The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. Mol Endocrinol 2002; 74: 1147-1152.
97. Ruiz M, Gafvels M, Eggertsen G, Carlstedt-Duke J, Nilsson L, Holtmann M. Characterization of two novel mutations in the glucocorticoid receptor gene in patients with cortisol resistance. Clin Endocrinol 2001; 55: 363-371.
98. Anderer G, Schrappe M, Brechlin AM et al. Polymorphisms within glutathione S-transferase genes and inital response to glucocorticoids in chilhood acute lymphoblastic leukaemia. Pharmacogenetics 2000; 10: 715-726.
99. Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia 2002; 16: 1437-1442.
100. Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 1995; 270: 27531-27537.
101. Bertram PG, Zeng C, Thorson J, Shaw AS, Zheng XF. The 14-3-3 proteins positively regulate rapamycin-sensitive signaling. Curr Biol 1998; 8: 1259-1267.
102. Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat 2001; 4: 378-391.